Details:

Alternative Title:
MMWR Morb Mortal Wkly Rep
Publisher's site:
http://dx.doi.org/10.15585/mmwr.mm6636a5
Personal Author:
Nelson, Noele P. ;
Corporate Authors:
National Center for HIV, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Viral Hepatitis. ;
Description:
GamaSTAN S/D (Grifols Therapeutics, Inc., Research Triangle Park, North Carolina) is a sterile, preservative-free solution of immune globulin (IG) for intramuscular administration and is used for prophylaxis against disease caused by infection with hepatitis A, measles, varicella, and rubella viruses (1). GamaSTAN S/D is the only IG product approved by the Food and Drug Administration for hepatitis A virus (HAV) prophylaxis. In July 2017, GamaSTAN S/D prescribing information was updated with changes to the dosing instructions for hepatitis A preexposure and postexposure prophylaxis indications. These changes were made because of concerns about decreased HAV immunoglobulin G antibody (anti-HAV IgG) potency, likely resulting from decreasing prevalence of previous HAV infection among plasma donors, leading to declining anti-HAV antibody levels in donor plasma (2). No changes in dosing instructions were made for measles, varicella, or rubella preexposure or postexposure prophylaxis.
Subject:
[+]
Full Report
Hepatitis A
Humans
Immunoglobulin G
Post-Exposure Prophylaxis
Practice Guidelines As Topic
Pre-Exposure Prophylaxis

Source:
MMWR Morb Mortal Wkly Rep. 66(36):959-960. ;
Pubmed ID:
28910270
Pubmed Central ID:
PMC5657912
Document Type:
Journal Article ;
Collection(s):
Morbidity and Mortality Weekly Report (MMWR)
Main Document Checksum:
[+]
urn:sha256:7552fc4e4f520d7b1b973cb9317ff46d3fcd9fd8d61782b2da2d10996a825112
File Type:

Supporting Files

• mm6636a5.nxml

  xml

More +